# EDGAR Filing Document

**Accession Number:** 0001904501
**File Stem:** 0001062993-25-015004
**Filing Date:** 2025-8
**Character Count:** 7939
**Document Hash:** 10df51f90e6038753f41b7db93a0e60c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001062993-25-015004.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001062993-25-015004

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250827

**FILED AS OF DATE**: 20250827

**DATE AS OF CHANGE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentek Ltd.
- **CENTRAL INDEX KEY:** 0001904501
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41310
- **FILM NUMBER:** 251266284

**BUSINESS ADDRESS:**
- **STREET 1:** 24 CORPORATE CT
- **CITY:** GUELPH
- **STATE:** A6
- **ZIP:** N1G 5G5
- **BUSINESS PHONE:** (844) 730-9822

**MAIL ADDRESS:**
- **STREET 1:** 24 CORPORATE CT
- **CITY:** GUELPH
- **STATE:** A6
- **ZIP:** N1G 5G5

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of <u>August 2025</u>**

**Commission File Number: <u>001-41310</u>**

<u>**ZENTEK LTD.**</u>

**(Registrant)**

**24 Corporate Court**

<u>**Guelph, Ontario N1G 5G5 Canada**</u>

 **(Address of Principal Executive Offices)**

Indicate by check mark whether the Registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐ Form 40-F ☒

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the Registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

<u>**SIGNATURES**</u><br>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZENTEK LTD.** | **ZENTEK LTD.** |
|  | (Registrant) | (Registrant) |
| Date: August 27, 2025 | By | /s/ Wendy Ford |
|  |  | Wendy Ford |
|  |  | Chief Financial Officer |

---

------

<u>**EXHIBIT INDEX**</u>

---

| | |
|:---|:---|
| <u>**Exhibit**</u> | <u>**Description of Exhibit**</u> |
| [99.1](exhibit99-1.htm) | [Press Release dated August 27, 2025 - Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency](exhibit99-1.htm) |

---

------

## Exhibit 99.1

------

![](exhibit99-1xu001.jpg)

<u>**Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency**</u>

Guelph, Ontario, August 27, 2025 - Zentek Ltd. (Nasdaq: ZTEK; TSXV: ZEN) ("**Zentek**" or the "**Company**") announces that on August 26, 2025, it received a written notification (the "**Notification Letter**") from the Nasdaq Stock Market LLC ("**Nasdaq**") that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company's common shares ("**Shares**") has been below US $1.00 per share for 31 consecutive business days.

The Notification Letter is only a notification of deficiency and not a notice of delisting. As such, the Notification Letter has no immediate effect on the listing or trading of the Company's Shares on the Nasdaq Capital Market under the symbol "ZTEK."

**Nasdaq Listing Rules**

Nasdaq Listing Rule 5550(a)(2) requires securities listed on the Nasdaq Capital Market to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's Shares for the 30 consecutive business days from July 14, 2025, to August 25, 2025, the Company has not met the minimum bid price requirement.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Zentek has a period of 180 calendar days, or until February 23, 2026, in which to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company's Shares must meet or exceed US $1.00 for at least ten consecutive business days during this 180-calendar day period. In the event Zentek does not regain compliance by February 23, 2026, the Company may be eligible for an additional 180 calendar day grace period if it meets the continued listing requirement for market value of publicly held shares (US $1 million) and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price and provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If it appears to Nasdaq that Zentek will not be able to cure the deficiency, or if Zentek is not otherwise eligible for additional time to regain compliance, Zentek's Shares will be subject to delisting by Nasdaq. Zentek may still appeal Nasdaq's determination to delist its Shares, and during any appeal process, Zentek's Shares would continue to trade on the Nasdaq Capital Market.

Zentek's management intends to actively monitor the bid price for its Shares and will consider all available options to regain compliance with the Nasdaq minimum bid price requirement.

The Company's business operations are not affected by the receipt of the Notification Letter.

**About Zentek Ltd.**

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener.

------

Zentek's patented technology platform ZenGUARD™, is shown to have 99-per-cent anti-microbial activity and to significantly increase the viral filtration efficiency for surgical masks and aims to do the same for HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.

Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

**For further information on Zentek:**

<u>investorrelations@zentek.com</u>

Ryan Shacklock

Senior VP, Strategy & Business Development

Email: <u>rshacklock@zentek.com</u>

Phone: 306-270-9610

To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.

**Forward-Looking Statements**

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

------